Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetanus peptide refers to synthetic peptide sequences derived from the tetanus toxoid protein produced by *Clostridium tetani*. These peptides, most notably the universal T-cell epitopes P2 (amino acids 830–844) and P30 (amino acids 947–967), are widely used in clinical vaccinology and cancer immunotherapy as "helper" components. Because most individuals have pre-existing immune memory from childhood tetanus vaccinations, these peptides can bind to a broad range of MHC class II molecules and stimulate CD4+ helper T-lymphocytes (HTLs). In the context of multi-peptide cancer vaccines, co-administration of a tetanus peptide provides the necessary cytokine environment and T-cell help to augment the activation and expansion of CD8+ cytotoxic T-lymphocytes (CTLs) against tumor-associated antigens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetanus peptide.